1. Pink Sheet
  2. >>Geography
  3. >>Europe

Gilead’s Lenacapavir, Takeda’s Maribavir Due For Oral Explanations At EMA

 
• By Vibha Sharma

The sponsors of four drugs were due or possibly due to appear before the European Medicines Agency to explain why their respective products merit EU-wide approval.  

Concept of EMA European Medicines Agency. Drugs evaluation and quality control, standards compliance department.
Oral explanations give companies a chance to explain why their drugs deserve EU-wide approval • Source: Shutterstock

Gilead Sciences is among the drug sponsors that were due to appear before the European Medicines Agency this week to explain why their products that are in the final stages of regulatory review should be recommended for EU-wide marketing approval. 

Gilead was due to speak at an oral explanation meeting regarding the marketing authorization application (MAA) for its HIV drug, lenacapavir, according to the draft

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography